Moxonidine Eg

Moxonidine, the active ingredient in Moxonidine Eg, is an imidazoline receptor agonist presented as an oral formulation for oral use. It lowers blood pressure in patients with essential hypertension. GNH USA supplies Moxonidine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine is an imidazoline I1‑receptor agonist used in the management of primary high‑blood‑pressure conditions.

Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension.

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary flow. - Dizziness: feeling light‑headed, especially on standing. - Fatigue: general tiredness or lack of energy. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: unusually slow heart rate. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or swelling. - Syncope: fainting episodes. - Electrolyte imbalance: especially with concomitant diuretics.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: adjust dose in patients with impaired kidney function. - Hepatic impairment: use cautiously if liver disease is present. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Concomitant antihypertensives: consider additive blood‑pressure‑lowering effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Moxonidine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Combined use with other antihypertensives (e.g., ACE inhibitors, ARBs) may cause excessive blood‑pressure reduction. - Co‑administration with clonidine can lead to severe hypotension.

Moderate Interactions (Monitor Closely): - NSAIDs may blunt the antihypertensive effect. - Diuretics can enhance hypotensive response. - Beta‑blockers may require dose adjustment. - Central nervous system depressants may increase dizziness. - Alcohol may potentiate hypotensive effects.